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INTRODUCTION
Colorectal cancer (CRC) is a frequent tumor with a
high mortality in Western countries (1). It represents 13%
of the total number of cancer cases diagnosed annually in
Asturias (Northern Spain) (2). Environmental factors
play a significant role in its induction (3); in fact, diets
high in fats, which are associated with increased fecal
concentration of secondary bile acids, are known to pro-
mote colon cancer (4,5).
Ursodeoxycholic acid (UDCA) is widely used for sev-
eral disorders (6-10). This bile acid had been described as
a cancer promoter both in epidemiological (11,12) and
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RESUMEN
Objetivos: analizar si la administración oral del ácido urso-
deoxicólico previene la aparición y desarrollo de carcinogénesis
colónica en ratas.
Material y métodos: ciento diez ratas de la raza “Sprague-
Dawley” de 10 semanas de vida, de ambos sexos, fueron divididas
en 5 grupos: a) 20 ratas control, sin tratamiento; b) 20 ratas, tra-
tadas con ácido ursodeoxicólico (AUDC), a 4 mg/kg/día, junto
con etanol, a 1,23 g/kg peso al día, añadidos al agua de bebida,
desde el principio del estudio y durante 24 semanas; c) 30 ratas,
18 dosis semanales, de 21 mg/kg peso de dimetilhidracina
(DMH) subcutánea, desde el principio del estudio, junto con las
mismas dosis de etanol y AUDC, que en el grupo B; d) 20 ratas,
18 dosis semanales subcutáneas de ácido etilen-diamino-tetracéti-
co; y e) 20 ratas, tratadas con las mismas dosis de etanol y las
mismas inyecciones de DMH, que el grupo C. El sacrificio de to-
dos los animales, se llevó a cabo en las semanas 25-27.
Resultados: no aparecieron tumores en ausencia de DMH.
No se observaron diferencias significativas en el número de ratas
que desarrollaron cáncer de colon, ni en el número de neoplasias
por rata, ni en los hallazgos macro-microscópicos de los tumores,
entre los animales del grupo C y del grupo E.
Conclusiones: la administración de ácido ursodeoxicólico, en
la dosis y tiempo utilizados no modificó la carcinogénesis colóni-
ca, usando un modelo dinámico de administración concomitante
de inducción tumoral con DMH en ratas.
Palabras clave: Cáncer de colon. Carcinogénesis. Dimetilhidra-
cina. Tumores. Ácido ursodeoxicólico.
ABSTRACT
Aims: the present study was designed to examine the effect of
ursodeoxycholic acid as chemoprotective agent in experimental
colon carcinogenesis in rats.
Material and methods: one hundred and ten 10-week-old,
Sprague-Dawley rats were divided into five groups: group A (20),
no treatment. Group B (20), receiving daily both ursodeoxycholic
acid (UDCA) 4 mg/kg of body weight and ethanol 1.23 g/kg of
body weight added to the drinking water from the beginning of
the study through 24 weeks. Group C (30), receiving 18 weekly
doses of dimethylhydrazine (DMH) 21 mg/kg of body weight sub-
cutaneously from the beginning of the study, with the same doses
of UDCA and ethanol as in group B. Group D (20), ethylen-di-
amin-tetracetic acid solution alone for 18 weeks. Group E (20),
receiving the same doses of ethanol plus DMH injections as in
group C. All experimental animals were sacrificed after 25-27
weeks.
Results: no tumors developed in dimethylhydrazine-free
groups. No significant differences in number of tumor-free ani-
mals, number of tumors per rat, and macro-microscopic tumor
findings were seen between animals in group C and animals in
group E.
Conclusions: we concluded that such an ursodeoxycholic
acid supplementation did not modify colorectal carcinogenesis us-
ing a dynamic DMH-induced model in rats.
Key words: Colon cancer. Carcinogenesis. Dimethylhydrazine.
Tumors. Ursodeoxycholic acid.
experimental studies. On the other hand, several authors
have confirmed its cytoprotective role in humans (13)
and in experimental conditions (13-15). It has been con-
sidered a chemoprotective agent (16,17), thus the dose
and timing required would have to be established.
Long-term prospective studies in humans are difficult to
carry out (18). The induction of colorectal cancer with 1-2
dimethylhydrazine (DMH) in rats is a currently valid ex-
perimental model that may transferred to humans (19-21).
The present study was designed to examine the effect
of ursodeoxycholic acid supplementation as chemopro-
tective agent on experimentally induced colon tumors in
both male and female rats.
MATERIALAND METHODS
This work belongs to the same experiment from which
several articles have already been published. A minimum
number of 20 rats per group was established in order to
achieve tumor induction using the dose and time estab-
lished for the DMH of 76-90% of rats (22,23); for a rate
of tumors in the rats induced by DMH of 1.60 (24,25)
and 1.87 (26-28); and a variable and high mortality ac-
cording to previous studies. In group C (the most impor-
tant group in this study) mortality was expected to be
higher than in the other groups, so the number of animals
in this group was increased related to availability.
UDCA administration alone was seen to produce in-
soluble residues in water, so as to induce aversion to wa-
ter. Based on these experimental findings, UDCA was
mixed with alcohol, so the risks of both a lower dose of
UDCA per rat and a heterogeneous consumption in
UDCA groups were avoided. Then, groups B, C and E
were to be designed.
A DMH group versus UDCA plus ethanol plus DMH
group design was not possible based on the uncertain ef-
fect of UDCA plus ethanol on colorectal carcinogenesis.
So, one hundred and ten 10-week-old “Sprague-Daw-
ley” rats (Lab Letica®, Barcelona, Spain), both male and
female and from the same genetic line, were distributed
into five groups. None of the 20 rats in group A (control
group) received any kind of treatment. The 20 rats of
group B (UDCA group) received ursodeoxycholic acid
(UDCA, Ursochol®, Zambon SA, Zambon Group,
Barcelona, Spain), at 4 mg/kg of body weight, and ethanol
1.23 g/kg of body weight, both added to the drinking wa-
ter from the beginning of the study until sacrifice. The 30
rats of group C (DMH and UDCAgroup) received 18 sub-
cutaneous (sc) injections weekly (24,25) with 21 mg/kg of
1,2-dimethylhydrazine (DMH; Fluka Chemica A.G., Sig-
ma Co.®, St. Louis, Missouri, USA) from the beginning
of the study, and were treated with the same volume of
ethanol and UDCA as those in group B. The 20 rats of
group D (EDTA control group) received the same subcu-
taneous volume of EDTA solution as those in group C,
mixed with only distilled water and without DMH. The
20 rats of group E (DMH + ethanol group) received the
same sc injections of DMH, and were treated with the
same volume of ethanol as the rats in group C.
The feeding was standard (ITM-R20 diet, Lab Letica®,
Barcelona, Spain), containing 3% fat and 5% fiber. Fifty
percent of animals from each group were weighed week-
ly until sacrificed. The volume of ethanol and UDCA
consumed by rats were controlled (29), and the total con-
sumption of drinking water was measured throughout the
study.
Room conditions were controlled, as recommended by
other authors (30,31). The animals were separated in
cages, for a maximum of three per cage, in order to avoid
autophagia (23-27). Animals of different gender were not
mixed in order to avoid aggression.
The recommendations of both the European Ethics
Committee (E.C. Directive number 609/86) and the text of
Royal Decree 1201/2005 of October 10 (published on Oct.
25 in Boletín Oficial del Estado) for the treatment of ex-
perimental animals were followed throughout the study.
Surviving rats were sacrificed between study weeks 25
and 27. A fixed and equal number of rats from each group
were sacrificed each week during the sacrifice period of
time (23-25).
At autopsy the number of tumors, and their localiza-
tion and size were all recorded. The tumor area was mea-
sured using the major and minor diameters (24,25,31,32),
and presented as the mean ± standard deviation (SD) (in
squared millimeters). Samples were later taken from the
cecum and ascending colon (right colon), and the trans-
verse and descending colon (left colon). Lesions in the
colonic mucosa were classified (33,34) according to their
degree of parietal invasion, differentiation, histological
type, association with lymphoid tissue, size, and macro-
scopic appearance. Other extra-intestinal findings were
also recorded.
Statistical analysis
A bivariate analysis was used for group comparisons,
especially between the DMH and UDCA (C) and DMH
(E) groups. For a comparison of mean values the ANO-
VA single-factor test was used. The SPSS-10.1 (Chicago-
Illinois) computer program for Windows was used for
statistical analysis. Differences between both groups
were significant when p value was equal to or less than
0.05.
RESULTS
Five rats (4.5%) died prior to study completion, 1 rat
from group C (3.3%), and 4 from group E (20%). Three
male rats did not complete the study because of an occlu-
sive tumor of the descending colon: one in group C, and
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two in group E. Thus, in group E one male rat developed
a colon tumor with metastases and digestive hemorrhage,
these being confirmed microscopically; and one female
rat died early with no tumor found. These animals were
therefore excluded from the analysis.
Alcohol consumption was similar in all ethanol-fed
groups (1.23 ± 0.0064 g/kg of body wt per day in group
B, compared to 1.23 ± 0.0071 in group C, and 1.23 ±
0.0094 in group E; p = 0.77). UDCA consumption was
similar in both UDCA-fed groups also (4 ± 0.0021 mg/kg
of body wt per day in group B, compared to 4 ± 0.0032 in
group C, p = 0.81). Neither diarrhea nor dehydration was
observed in rats that finished the study, when adding al-
cohol and UDCA to the drinking water.
No significant differences were found between the
weight of animals in group C and group E: in male rats,
531.64 ± 78.71 g and 556.82 ± 27.68 g, respectively (p =
0.30); in female rats, 316.02 ± 23.30 g and 307.50 ±
35.90 g, respectively (p = 0.15).
No tumors were seen in the animals of DMH-free
groups (A, B, and D).
Tumors developed in DMH-treated groups only: no
differences were observed in the mean number of tumors
or in the number of tumor-free rats (Table I).
No significant differences were found in tumor size, or
in macroscopic morphology, or in tumor location for rats
in group C as compared to rats in group E (Table II).
Microscopic findings (Table III) revealed no differ-
ences for animals in group C when compared to those in
group E in terms of number or histological type, or re-
garding extent of invasion or differentiation, or in tumor
association with lymphoid tissue.
However, rats in group C had a significantly higher
number of mucinous carcinomas in the right colon (75%)
when compared to those found in the left colon (13.5%; p
= 0.003). For rats in group E this trend was also observed
(p = 0.31) (Table IV). In group C, 2 female rats devel-
oped a mucinous and poorly differentiated colonic tumor
with hepatic metastases, confirmed microscopically.
Two small-bowel tumors were also found in group C:
one in a male rat and one in a female rat that developed
peritoneal carcinomatosis.
DISCUSSION
The induction of colorectal cancer in the rat with 1-2
dimethylhydrazine (DMH) is currently a valid experi-
mental model that may be transferred to humans given
that tumors induced with DMH are similar in these two
species, both in their macro-microscopic and clinical be-
havior (19-21).
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Table I. Tumor incidence and distribution
DMH + UDCA + OH DMH + OH
Group C (n = 29) Group E (n = 16)
Number of rats sacrificed, n (%) 29 (96.7) 6 (80)
Male/female, n 14/15 7/9
Number of tumor-free rats, n (%) 7 (24.1) 6 (37.5)
Male, n (%) 3/14 (21.4) 1/7 (14.3)
Female, n (%) 4/15 (26.7) 5/9 (55.6)
Total number of tumors, n (%) 28 (96.5) 16 (100)
Male/female, n 15/13 12 / 4
Mean number tumor/rat, mean ± SD 1.45 ± 0.66 1.60 ± 1.02
Male 1.55 ± 0.82 2 ± 0.89
Female 1.18 ± 0.66 1 ± 0
UDCA: ursodeoxycholic acid; OH: ethanol; SD: standard deviation; DMH: di-
methylhydrazine; n: number of cases.
Table II. Macroscopic characteristics of tumors
DMH + UDCA + OH DMH + OH
Group C (n = 29) Group E (n = 16)
Mean tumor size, mm2 ± SD 85.64 ± 113.05 45.87 ± 53.13
Male 57.73 ± 56.07 39.08 ± 49.69
n = 15 n = 12
Female 117.85 ± 65.76 66.25 ± 65.76
n = 13 n = 4
Macroscopic tumor findings, n (%)
Polypoid 19 (67.9) 13 (81.3)
Normal mucosa 2 (7.1) 2 (12.5)
Other morphologies 7 (25) 1 (6.2)
Tumor distribution in colon, n (%)
Right colon 12 (42.9) 7 (43.8)
Left colon 16 (57.1) 9 (56.2)
UDCA: ursodeoxycholic acid; OH: ethanol; SD: standard deviation; DMH: di-
methylhydrazine; n: number of cases. Tumor size is expressed as the greatest tu-
mor area in squared millimeters.
Table III. Microscopic characteristics of tumors
DMH + UDCA + OH DMH + OH
Group C (n = 29) Group E (n = 16)
Histological type, n (%)
Adenocarcinomas 17 (60.7) 8 (50)
Mucinous adenocarcinomas 11 (39.3) 8 (50)
Degree of differentiation, n (%)
High 11 (39.3) 4 (25)
Moderate 5 (17.8) 5 (31.3)
Poor 12 (42.9) 7 (43.7)
Extent of invasion, n (%)
In situ carcinoma 7 (25) 4 (25)
Peritoneal involvement 5 (17.9) 1 (6.3)
Other 16 (57.1) 11 (68.7)
Associated lymphoid tissue, n (%) 5 (17.9) 5 (31.3)
UDCA: ursodeoxycholic acid; OH: ethanol; SD: standard deviation; DMH: di-
methylhydrazine; n: number of cases.
Table IV. Tumor classification in relation to location
DMH + UDCA + OH DMH + OH
Grupo C (n = 29) Grupo E (n = 16)
Right colon, n 12 7
Tumor size, mm2 ± SD 116.67 ± 108.64 45.43 ± 57.42
Adenocarcinomas, n (%) 3 (25) 2 (28.6)
Mucinous carcinomas, n (%) 9 (75)* 5 (71.4)
Left colon, n 16 9
Tumor size, mm2 ± SD 62.38 ± 114.03 46.22 ± 53.11
Adenocarcinomas, n (%) 14 (87.5) 6 (66.7)
Mucinous carcinomas, n (%) 2 (13.5)* 3 (33.3)
*p = 0.003 (adenocarcinomas versus mucinous carcinomas of left colon in DMH
and UDCA group). UDCA: ursodeoxycholic acid; OH: ethanol; SD: standard de-
viation; DMH: dimethylhydrazine; n: number of cases. Tumor size is expressed as
the greatest tumor area in squared millimeters.
An incidence of spontaneous experimental colonic
carcinogenesis below 2-3 rats/100,000 rats observed is
reported (35). In the absence of carcinogen (DMH) no
rats developed tumors, as expected.
Diets high in fat, which are associated with increased
fecal concentration of secondary bile acids, are known to
promote colon cancer (4,5). Ursodeoxycholic acid
(UDCA), the 7-B-epimer of chenodeoxycholic acid, is a
bile acid widely used in humans (6-10).
With the amounts of ethanol (25) and UDCA de-
scribed, animals showed no natural aversion to them, and
we did not expect any differences in consumption be-
tween groups, as it was. Thus, we supplemented them us-
ing the designed dose and timing required by this study.
This work stems from the same experiment from
which several articles have already been published.
Based on them, in a dynamic model of concomitant ad-
ministration of ethanol and procarcinogen (36-38), at the
dose and timing established (25,39-41), this relatively
low dose of ethanol would had not been dangerous
enough to modify colorectal carcinogenesis.
In human studies (11) UDCA is metabolized to the 7-B-
epimer of chenodeoxycholic acid, whose mechanism of
action resides in its conjugation with nitrosamines at the
intestinal epithelium, with mutagenic properties, by the lu-
minal route. In experimental studies in rats this effect
could be explained by an increased permeability mediated
by mast cells (42), increased cell proliferation rate (12,30),
and diminished activity of alkaline sphingomyelinase in
the epithelium (43), which is also observed in human
pathology. This was not observed in our rats.
In epidemiologic studies a significant reduction in
stool deoxycholic acid concentrations (as a biomarker of
cell damage) has been described at a dose of 4 mg/kg
body wt per day for 3 weeks (13). Other authors (44)
found a significant reduction of the risk for colon cancer
at 13-15 mg/kg body wt per day for 12 years. Moreover,
it has been reported some kind of prevention for colon
cancer at 9-10 mg/kg body wt per day for 6-14 years (5),
and for high-grade dysplasia at 8-10 mg/kg body wt per
day for 3 years (16).
Taking these studies together, data suggest that chemo-
prevention seems to be time- and dose-response- related.
Nowadays, its applicability to cancer prevention re-
mains uncertain, and the dose and critical timing of UDCA
supplementation would have to be established (17). In ex-
perimental studies in rats this protective effect could be ex-
plained by the inhibited expression of both K-ras oncogene
and cyclooxygenase-2 activity in tumor cells (15); thus, a
slower progression of the adenoma-carcinoma sequence
has also been involved (14,45).
In our study, the minimum dose schedule of 4 mg/kg
body wt per day was used as a chemopreventive dose
against colon cancer. Our results show no significant dif-
ferences either in the number or in the macro-microscopic
characteristics of tumors in DMH-induced rats (groups C
and E), so that this relatively low dose of UDCA was not
effective enough to show any chemopreventive effect.
Nevertheless, there were some parameters, including tu-
mor size, that have shown no significant differences be-
tween their mean values, despite a high gap between
them; and others, including tumor location, that have at-
tained statistical significance without this apparent gap of
difference. It seems that the number of animals per group
could have altered our results, and avoided demonstrating
the possible protective effect of UDCA.
Moreover, a dynamic model of concomitant administra-
tion of UDCA and procarcinogen is a controversial design
for studying colorectal carcinogenesis. UDCA when sup-
plemented during the initiation phase of carcinogenesis
significantly decreased the total number and size of aber-
rant crypt foci (ACF, as a cell hyperproliferation marker)
and was effective in preventing tumor occurrence, but giv-
en in promotion/progression and post-initiation phases, at
the same doses as in our study for 2 weeks, failed to alter
the number or size of ACF (14). Based on these findings
the concomitant administration used in our study could
also have inhibited the chemoprotective effect.
As in human pathology, a mucinous adenocarcinoma
is considered a poorly differentiated tumor with a behav-
ior different to that of a non-mucinous one (33). As in
previous studies (25), a significantly greater number of
mucinous adenocarcinomas were found in the right colon
of rats within group C when compared to the left colon of
these same animals.
In our study, as suggested by some authors (46-49), we
have been able to demonstrate a different behavior be-
tween both sides of the colon. Right tumors therefore
showed their own and worse behavior when compared to
left tumors and this effect was not modified by exoge-
nous ethanol and UDCA delivery. Our results are not
comparable to those of other authors (28,50) due to the
different histological criteria used (33,34), following our
previous studies (24,25,51).
Finally, we conclude that oral UDCA supplementation
at a dose of 4 mg/kg body wt per day for 24 weeks did
not modify colon cancer in a dynamic model of carcino-
genesis induced by DMH in Sprague-Dawley rats. And
secondly, that a different histological behavior did exist
in tumors located in the right colon compared to left ones,
and the external agents used (UDCA and ethanol) did not
modify it.
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